The neuropeptide substance P (SP), encoded by the preprotachykinin-A (PPTA) gene, is expressed in the central and medial amygdaloid nucleus, where it plays a critical role in modulating fear and anxiety related behaviour. Determining the regulatory systems that support PPTA expression in the amygdala may provide important insights into the causes of depression and anxiety related disorders and will provide avenues for the development of novel therapies. In order to identify the tissue specific regulatory element responsible for supporting expression of the PPTA gene in the amygdala, we used long-range comparative genomics in combination with transgenic analysis and immunohistochemistry. By comparing human and chicken genomes, it was possible to detect and characterise a highly conserved long-range enhancer that supported tissue specific expression in SP expressing cells of the medial and central amygdaloid bodies (ECR1; 158.5 kb 5 0 of human PPTA ORF). Further bioinformatic analysis using the TRANSFAC database indicated that the ECR1 element contained multiple and highly conserved consensus binding sequences of transcription factors (TFs) such as MEIS1. The results of immunohistochemical analysis of transgenic lines were consistent with the hypothesis that the MEIS1 TF interacts with and maintains ECR1 activity in the central amygdala in vivo. The discovery of ECR1 and the in vivo functional relationship with MEIS1 inferred by our studies suggests a mechanism to the regulatory systems that control PPTA expression in the amygdala. Uncovering these mechanisms may play an important role in the future development of tissue specific therapies for the treatment of anxiety and depression.
Introduction
Depressive and anxiety related disorders will affect 25% of individuals in developed countries at some point in their lives (National Institute of Mental Health statistics). Furthermore, the incidence of these disorders is closely linked to increased morbidity and mortality rates. 1 Despite a great deal of evidence indicating a strong genetic component to depression and anxiety related disorders, 2 the genetic systems that govern the modulation of anxiety and depression remain obscure.
In clinical and experimental studies, the amygdala has been shown to be at the centre of the neuroanatomical circuitry responsible for the perception and modulation of fear, stress and anxiety. 3 The amygdala is a key part of the limbic system and is comprised of many subnuclei, which are characterised by their efferent and afferent connections. 4 All of the nuclei forming the amygdala have been shown to be involved in the generation, regulation and expression of anxiety/stress responses 5 For example, the involvement of the central amygdala (CeA) in the stress incurred by opiate withdrawal and alcoholism is well documented. 6, 7 Furthermore, the CeA referred to as the 'nociceptive amygdala' as a result of its perceived role in integrating pain inputs to the amygdala. 8 Additionally, the medial amygdala (MeA) seems to play an important role in predator odourinduced fear behaviour in rodents. 9 A number of different neuropeptides that include corticotrophin-releasing factor (CRF) Neuropeptide Y (NPY) Cholescystokinin (CKK), Galanin and substance P (SP) are expressed in the amygdala and each has been shown to be responsible for modulating aspects of fear and anxiety related behaviour through their respective receptors. [5] [6] [7] [8] [9] [10] Together with inputs from classical neurotransmitter pathways that derive from serotonin (5-HT), Dopamine (DA), GABA and Norepinephrine (NE) neurons, the expression of these neuropeptides in the amygdala comprise critical components of the complex regulatory systems that control feelings of fear and anxiety. 10 It is therefore highly probable that polymorphism/mutation induced changes in the components of the regulatory systems of any of these neuropeptides in the amygdala may lead to susceptibility to anxiety and depressive disorders. 11 Because of its recently recognised role in the modulation of fear and anxiety related behaviour, the tachykininergic system is currently being actively considered as an alternative source of potential drug targets with a view to developing novel antidepressive and anxiolytic therapies. [12] [13] [14] The tachykinins are a group of neuropeptides that include SP, NKA (encoded by the preprotachykinin-A (PPTA) gene that is also known as TAC1), NKB (encoded by the PPTB gene) and Hemokinin (encoded for by PPTC). 15 The physiological effects of the tachykinins are transmitted via a family of three different G-proteincoupled receptors called NK-1, NK-2 and NK-3 that display distinct binding preferences for particular tachykinins. 15 Thus, NK1 displays a distinct preference for the binding of SP. 16 Interest in the involvement of the tachykinins in modulating mood was first sparked by the observation that NK1 and SP knockout mice displayed significantly less fear and anxiety related behaviour, and were more aggressive than wild-type mice. 17, 18 Furthermore, it was shown that both the NK1 receptor and its ligand SP are expressed in the amygdala. 19, 20 Recent experiments have also shown that exposing rodents to chronic stress increases the transcription of PPTA and elevates levels of SP release in the MeA. 21, 22 Significantly, specific addition of antagonists against the SP receptor (NK1) into the MeA was demonstrated to reduce fear and anxiety related behaviour, whereas injection of SP agonists increased this behaviour. 22 One of the most striking pieces of evidence linking SP/NK1 interaction to the modulation of mood is based on the decrease in feeling of fear and anxiety experienced by chronically depressed patients, who were given the NK1 antagonist MK-869. 23, 24 Furthermore, the possibility that PPTA may be involved in conferring susceptibility to depressive disorders was suggested by the results of an expanded convergent functional genomic screen that highlighted the possible role of the PPTA gene in contributing to bipolarrelated disorders. 25 The complexities of the regulatory systems controlling anxiety-related behaviour in the amygdala were highlighted following studies designed to remove NK1 expressing cells within the amygdala. In this study, Gadd et al. 26 specifically ablated NK1 expressing cells by application of a compound consisting of SP conjugated to the toxin saponin. Unexpectedly, removal of NK1 expressing cells from the amygdala resulted in elevated levels of anxiety-related behaviour in test animals. These results are puzzling in the light of previous data supporting the anxiogenic role of the SP-NK1 interaction within the amygdala. Hence, it would be expected that removal of NK1 expressing cells would result in a less anxious phenotype. However, the results of these experiments may be explained if we accept that other non-NK1 mediated regulatory pathways with potent anxiolytic properties are involved in modulating anxiety-related behaviour within NK1 expressing cells. Therefore, in addition to perturbing the SP-NK1 system, ablation of these NK1 expressing cells would also disrupt a number of other systems resulting in a net anxiogeneic output from the amygdala. The results of these NK1 cell deletion experiments underline how little is known about the molecular interactions that control anxiety and the importance of further examining the regulatory systems that cascade and intermesh through the amygdala to modulate anxiety.
Despite the known importance of the role of SP in the amygdala in modulating fear and anxiety related behaviour virtually nothing is known about the tissue specific or inducible regulatory systems that control the transcription of the PPTA gene in this critical region of the brain. Identification of the components of these systems, and how they interact to produce relevant tissue specific expression of the PPTA gene, will greatly contribute to a better understanding of why many individuals are more susceptible to anxiety and depressive disorders, and will allow the design of more effective and specific theraputic strategies.
Previous studies to define these regulatory systems have used transformed cell lines 27 and organotypic cultures 28, 29 to describe the presence of regulatory elements within 3.3 kb of the PPTA start site. 27 However, transgenic analysis using this 3.3 kb failed to induce any specific marker gene expression in any cells of the amygdala that also expressed PPTA or substance-P indicating that these putative regulatory elements were not functional in the amygdala in vivo. 30, 31 In order to ascertain the extent of the genome required to produce tissue specific expression of the PPTA gene, we engineered a yeast artificial chromosome (YAC) in which the LacZ gene was fused in-frame to the human PPTA gene. The production of transgenic lines with this YAC construct demonstrated that the regulatory elements required for expression of PPTA in the amygdala lay within 240 kb 5 0 and 140 kb 3 0 of the PPTA start site. 11, 27, [31] [32] [33] In preference to carrying out an extended and wasteful deletion analysis of the YAC construct we tested the hypothesis that the enhancers responsible for driving the expression of the PPTA gene have been highly conserved during evolution and could be located using predictive bioinformatics.
The present study describes the use of long-range post-genomic bio-informatic analysis of the human and chicken genomes to identify a highly conserved regulatory element 158.5 kb 5 0 the human PPTA gene that is able to support expression of a marker gene in A remote amygdala specific PPT-A enhancer S Davidson et al cells of the MeA and CeA that also expressed SP. Furthermore, we provide evidence of an interaction between a transcription factor (TF) called MEIS1 and the ECR1 enhancer in the CeA in vivo. The discovery of ECR1 is a major step towards understanding the regulatory systems that control the expression of the PPTA gene in the amygdala where its product; SP, plays a critical role in modulating fear and anxiety related behaviour. A better understanding of these regulatory systems and how these systems may go wrong will greatly facilitate in the future design of more specific and efficacious therapies for the treatment of depressive and anxiety related disorders.
Materials and methods

Bioinformatic analysis
Chicken sequence for analysis was recovered from the Ensembl web site (http://www.ensembl.org/). Genome comparisons (phylogenetic footprinting) using these recovered sequences were carried out using rVISTA (http://pipeline.lbl.gov/cgi-bin/gateway2) and the ECR browser (http://ecrbrowser.dcode.org/). 34 Detection of TF binding consensus sequences was carried out using the web based MATCH (http:// www.gene-regulation.com/cgi-bin/pub/programs/match/ bin/match.cgi) programme that use the publicly available TRANSFAC 6.0 database 35 (http://www. gene-regulation.com/cgi-bin/pub/databases/transfac/ search.cgi).
Cloning of ECR1
ECR1 sequence used in this study was isolated from human placental DNA using high fidelity PCR (Expand HiFi system, Roche) using the following oligonucleotide primers; ECR1_FOR: TCAAGATAAT TTTGCCATGCTG; ECR1_REV: GATCGGTATAGCAA ACCACCA (MWG). PCR products were blunt end cloned into pGEM5z (Promega) and sequenced (ABI 377 sequencer) to determine amplification fidelity. PCR products were then ligated into the well-characterised reporter construct p1230 36 to produce the plasmid construct pECR1-hbg-LacZ. p1230 has been used successfully many times in the past and the human b-globin promoter has been demonstrated to be incapable of supporting any degree of consistent tissue-specific expression of the LacZ gene on its own within transgenic animals. 31, [36] [37] [38] This construct was then linearised using NotI and ApaI digestion and gel purified for pronuclear microinjection.
Transgenic analysis
Construct DNA was microinjected into 1-cell C57/ BL6xCBA F1 mouse embryos at a concentration of 2-4 ng/ml À1 as previously described. 39 Surviving embryos were oviduct transferred into pseudopregnant CD1 host mothers. 39 
Histological analysis
Transgenic mice from each line were humanely sacrificed by halothane overdose and perfused using 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS). These mice were dissected to recover brain, spinal cord and dorsal root ganglia. Tissues were further fixed in 4% PFA (PBS) for 2 h. Whole brains were then sectioned frontally into 4 mm thick slices. All tissues were then stained using 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-gal) solution for 4-12 h as described. 39 X-gal stained tissues were then either prepared for vibratome sectioning or for analysis by immunohistochemistry. For vibratome sectioning, tissues were impregnated with increasing concentrations of sucrose (to 20%) in PBS at 41C. Tissues were then impregnated with BSA/Gelatin solution (0.5% gelatin, 20% sucrose, 15.5% bovine serum albumen (BSA)) overnight at 41C. BSA/Gelatin embedded tissue was then hardened by addition of one-tenth of a volume of 25% gluteraldehyde. 50 mm sections were then cut on a Vibratome series 1000. Sections were mounted on glass slides and photographed under light field or phase contrast illumination.
Immunohistochemical analysis
For immunohistochemistry analysis X-gal stained tissues were fixed overnight in 4% paraformaldehyde and impregnated with ascending concentrations of sucrose (to 20%) in PBS. Sucrose impregnated tissues were snap frozen in liquid nitrogen and mounted for sectioning in OCT compound. Sections (10 mm) were cut on a cryotome and mounted on polysine slides. Sections were preincubated in 5% donkey serum and 10% BSA in PBS for 1 h then washed three times in PBS. Sections were then incubated for 48 h at 41C with 1:5000 dilution of Rabbit anti-SP antibody (Chemicon) or 1:5000 rabbit anti-MEIS1 (A kind gift from Arthur Buchberg). Sections were then washed in PBS Â 5 and incubated with Alexa fluor 488 donkey anti-rabbit IgG secondary antibody (Molecular Probes). Following three washes in PBS sections were mounted in Vectasheild with DAPI (Vector labs) or propidium iodide (10 mg/ml) and either photographed under fluorescent microscopy or using a Ziess confocal microscope set to optically section 1 mm slices.
Result
Comparative analysis of mammalian genomes Using transgenic analysis of a 380 kb YAC construct containing the PPTA gene fused to a LacZ reporter, we have previously demonstrated that the elements required for expression of the PPTA gene in the amygdala, lay within 140 kb 3 0 or 240 kb 5 0 of the PPTA transcriptional start site. 32, 33 In order to determine the locations and identity of the enhancers responsible for driving expression of the PPTA gene in the amygdala within this 380 kb, we carried out genome comparisons using the ECR browser 34 set to detect regions of significant conservation between chicken, mouse, rat, dog and human genome sequences surrounding the PPTA gene. Comparing mammalian sequence alone led to the identification of upwards of 40 peaks of genome homology (greater than 70% over 100 bp) within the 380 kb of the human genome contained within the previously analysed YAC construct, 32, 33 suggesting that the expression of the PPTA gene either depended on many different enhancers or that the peaks of conservation observed represented high levels of conserved sequence with little-tissue specific influence on transcription ( Figure 1a) . We have previously cloned several of these regions of high mammalian homology and have tested their ability to drive the expression of marker genes in transgenic animals. These analyses were inconclusive in as much as none of the transgenic animals generated (as tested by PCR) demonstrated any degree of marker gene expression that was consistent with the known distribution of the PPTA mRNA transcripts (data not shown). These results are consistent with the hypothesis that many of the highly conserved regions flanking the PPTA gene represent conserved genetic 'noise' and do not represent tissue specific PPTA enhancers.
Chicken-human genome comparisons
Comparative analysis of 380 kb of the human and chicken genome corresponding to the sequence contained within the previously analysed 380 kb PPTA containing YAC construct previously analysed 32, 33 succeeded in revealing two evolutionary conserved regions (ECR) of significant conservation within 240 kb 5 0 of the PPTA gene ( Figure 1a ). The closest sequence to the PPTA locus, evolutionary conserved region 1 (ECR1) exhibited 74% sequence conservation over 217 base pairs between chicken and human and was located 158.5 kb 5 0 of the human PPTA gene transcriptional start site (Figure 1b) . The persistent cis-linkage of these remote and highly conserved sequences with the PPTA gene, despite 310 million years of evolutionary divergence 40 and strong evidence for the occurrence of much higher chromosome rearrangement rates between species 41, 42 is entirely consistent with the hypothesis that ECR1 is responsible for supporting the expression of the PPTA gene.
Transgenic analysis of ECR1
We used high fidelity PCR to isolate the human ECR1 sequence and cloned it into a plasmid containing the bacterial LacZ marker gene linked to the human bglobin promoter (p1230) to form pECR1-hbg-LacZ. Linearised pECR1-hbg-LacZ plasmid was microinjected into 1-cell mouse embryos to generate pECR1-hbg-LacZ transgenic lines. Three pECR1-hbg-LacZ transgenic lines (representing three separate transgene integration events) that we analysed by whole mount LacZ staining and vibratome sectioning demonstrated a strong and consistent LacZ staining pattern within cells of an area of the brain that coresponded to the medial amygdaloid nucleus (Figure 2a and b) . LacZ staining was also detected within the central amygdaloid nucleus (Figure 2c and d) and could also be detected within parts of the thalamus corresponding to the zona incerta (Figure2a and b) and a restricted population of cells within the caudate putamen (Figure 2c and d) . These areas of the amygdala are entirely consistent with the previously described locations of PPTA expression, 21 localisation of the SP peptide 19 and LacZ expression from PPTA YAC transgenic lines 33 in the amygdala, thalamus and the caudate putamen. In order to determine whether expression of LacZ from the transgene corresponded to the expression of the SP peptide at the cellular level, we carried out fluorescent immunohistochemistry using antibodies against SP on transgenic tissue sections previously stained with X-Gal. We were able to observe the colocalisation of b-galactosidase activity and the expression of SP within populations of cells of the medial and central amygdaloid nucleus (Figure 2e-h ). Although one of the lines generated also displayed ectopic transgene expression in regions within the cerebellum (data not shown), additional consistent transgene expression relating to the known expression of the PPTA gene was not detected in other regions of the brain or peripheral nervous system in any of the lines examined.
TRANSFAC analysis of ECR1
In order to predict the identity of the TFs that interact with ECR1, we subjected ECR1 sequence to analysis using MATCH; a publicly available web tool that allows detection of known TF consensus binding sequences (matrices) based on TRANSFAC data sets. We examined the presence of TF binding sites using stringent conditions where core binding site similarity equalled 100% (core sim. = 1) and where matrix similarity was greater that 90% (mat.sim. > 0.9). The core similarity denotes the quality of a match between the most conserved five nucleotides of a TF binding matrix and ECR1. The matrix similarity is a score that describes the quality of a match between the entire TF binding matrix and ECR1. The matrices of all the TFs in the TRANSFAC database are empirically deduced by electrophoretic shift assays and site selection enrichment assays using random oligos. 43 Using these utilities set to the stringent parameters described, we were able to detect the binding consensus sequences of many different TFs that included the Y-box binding factor nuclear factor Y (NF-Y; 2 binding sites), CCAAT/enhancer binding protein alpha (C/EBP; 2 binding sites), ETS-1 (1 binding site 44 ), AP-1 (3 binding sites), TGIF (3 binding sites), AREB6 (1 binding site) and MEIS1 (4 binding sites; Figure 1) . Interestingly, many of these TF-binding sites, in addition to being highly conserved, also occurred several times within the most conserved 217 bp of the ECR1 element. Furthermore, the mRNA and protein distribution of several of these TFs closely corresponds to that of the activity of the human PPTA promoter. For example, we are able to show that embryos from the YAChPPTALacZ transgenic lines demonstrate PPTA promotor activity in areas of the developing embryo brain that overlap that of both the mRNA and protein expression of the MEIS1 homoebox gene 45 in an area of the brain destined to give rise to the amygdala (Figure 2i and j) . Therefore, MEIS1 was a good candidate for controlling the expression of the PPTA gene via binding of the ECR1 enhancer. Figure 1 (a) Graphical representation of the results of a phylogenetic footprint study (using the ECR browser) comparing chicken (top graph), rat (middle graph) and mouse (bottom graph) genome sequence against the human sequence. The X-axis on each graph represents distance in reference to 324.6 kb of the human genome and the Y-axis represents degrees of homology between 50 and 100% over 100 base pair blocks. Red peaks represent areas of the respective genome with greater than 75% homology over 100 base pairs to the human genome. Blue peaks represent coding conservation within the PPTA gene (TAC1). Light grey boxes (underlined with green lines) represent areas of recognised repetitive DNA. ECR1; evolutionary conserved region 1. (b) Comparison of ECR1 sequences from six different species. Areas of sequence homology between all six species are highlighted with red filled boxes. Transcription factor binding sites as predicted by MATCH (matrix similarity = 0.90, core similarity = 1) using the TRANSFAC database are highlighted as areas of coloured sequence above each of the lines of sequences. The identity of each of the transcription factor binding sites is indicated using a colour key displayed in the bottom right of the figure. Any nucleotides within the sequences that cannot be matched to any of the matrices displayed in the Transfac database are represented in black. MEIS1 binding sites are numbered 1-4 to aid identification in the Results and Discussion section.
Cellular colocalisation of neuclear MEIS1 expression and ECR1 enhancer activity
In order to test whether MEIS1 was involved in regulating the activity of the ECR1 enhancer in adult amygdala, we carried out immunohistochemical analysis of brain sections of animals transgenic for the pECR1-hbg-LacZ construct. Using fluorescent confocal microscopy we were able to detect the . 45 (j) Expression of b-galactosidase expressed in a the medial and lateral ganglionic eminences of a coronal section through an E12.5 mouse embryo fore brain transgenic for the YAChPPTALacZ expression construct. 32, 33 Cort, cerebral cortex; Hipp, hippocampus; Thal, Thalamus; Amyg, amygdala; MeA, medial amygdala; MGP, med globus pallidus; Cpu, caudate putamen; CeM, central amygdaloid nucleus; ZI, zona incerta; MGE, medial ganglionic eminence; LGE, lateral ganglionic eminence. Scale bar in E = 50 mm.
presence of the MEIS1 TF in a subpopulation of cells within the amygdala that represented approximately 5% of the overall cell population. This population of MEIS1 expressing cells was divided into cells demonstrating either cytoplasmic or nuclear staining of MEIS1 (see Figure 3c) . None of the cells exhibiting cytoplasmic expression of MEIS1 demonstrated any expression of the transgene (Figure 3d , red arrow heads). However, we were able to observe that greater than 95% of the cells of the CeA that contained observable nuclear MEIS1 immunoreactivity also demonstrated b-galactosidase activity (Figure 3d , yellow arrow heads). In combination with the presence of many highly conserved MEIS1 binding sites within the ECR1 enhancer, this observation is entirely consistent with the hypothesis that MEIS1 and ECR1 are components of a highly conserved regulatory system involved in modulating PPTA expression in the CeA. Similar coexpression was not seen in LacZ staining cells of the thalamus or MeA.
Discussion
Individual susceptibility to chronic depression and anxiety related disorders has been shown to have strong, although complex, genetic components. [46] [47] [48] [49] Because of their relative ease of identification the genetics of susceptibility to these diseases has most often been examined from the perspective of exonic sequence to detect polymorphisms that either alter or curtail the biochemical activity of particular proteins. In comparison, little has been done to determine the role that gene mis-expression may play in the development and exacerbation of psychiatric disease. Gene mis-expression at the transcriptional level might result from mutations within the coding sequences of trans-acting factors or rearrangements/mutations of essential cis-acting elements (core promoters, enhancers and silencers). A link between differences in gene expression and disease susceptibility was suggested by recent microarray-based gene expression profiling studies that demonstrated that gene expression levels between individuals of the same species can vary enormously. 50 In addition, this variance in expression has been shown to be governed by a strong heritable component that, in many cases, is cisacting. 51, 52 It is therefore highly likely that the incidence of susceptibility to depressive and anxiety related illness is a function of individual differences within components of the regulatory systems that control the expression of genes that affect mood as opposed to mutations within the coding sequences of these genes. However, very little is known about the regulatory systems that control the expression of these genes.
Because of its expression characteristics in the amygdala, 21 its known role in the modulation of fearrelated behaviour 22 and its suggested linkage to incidence of bipolar-related behaviour, 25 the PPTA gene and its peptide products have recently attracted a great deal of attention from pharmaceutical companies interested in developing novel drug therapies against the causes of depressive and anxiety related disorders. Despite these known properties of PPTA and its products little is known about the regulatory systems (ligand-receptor interactions, signal transduction pathways and protein-DNA interactions) that regulate the expression of PPTA in the amygdala. Understanding these regulatory systems will facilitate in the development of more specific antidepressive therapies.
In an effort to determine the cis-regulatory components of the regulatory systems that control PPTA in the amygdala, we carried out long-range comparative genomic analysis of a wide range of different vertebrate species. Comparisons of the chicken and human genome sequence described in the current study was able to highlight the location of a small region of significant sequence homology at some 158.5 kb distance 5 0 of the PPTA gene. Subsequent isolation and transgenic analysis of this sequence was able to confirm that it represented a remote but tissue specific enhancer that was able to drive the expression of a marker gene into substance-P expressing cells of the CeA and MeA. The high levels of evolutionary conservation within ECR1 in addition to its activity in SP expressing cells of the amygdala is consistent with the known critical role in mood modulation played by the PPTA gene in the amygdala. These observations further support the contention that PPTA expression in the amygdala is an essential and highly conserved component of the 'fight or flight' response that allowed our remote ancestors to survive in a hostile predatory environment.
We further used bio-informatic analysis to predict several of the TF components of the regulatory systems controlling PPTA expression in the amygdala. Using stringent selection criteria, we were able to detect the multiple conserved binding sites of several different TFs. The binding consensii of all the TFs described in the Transfac database have been established empirically beforehand through extensive laboratory experimentation. 43 Furthermore, several studies in the past have been successful in using bioinformatics applications such as Transfac to identify the binding consensii of known TFs. [53] [54] [55] Therefore, because of the high stringency selection parameters described to detect TF binding consensii in ECR1 and the observation that many of these binding sites have been highly conserved through evolution, there is little doubt that the TFs in question will bind to ECR1 in vitro although their interaction with ECR1 in vivo remains to be fully explored. Many of these TFs, such as AP-1 have three binding sites within the ECR1 sequence. The observation that multiple and highly conserved AP-1 binding sites are present within ECR1 is interesting as a number of previous studies have described the expression of fos and jun in the amygdala. 56, 57 Further studies have determined that, in parallel with the expression of PPTA, both the expression and activity of fos and jun are unregulated in the amygdala in response to stress. 57, 58 In addition, the highly conserved binding sites of the C/EBP protein are represented twice in ECR1. This observation is interesting as mice deficient for members of the C/EPB family display increased fear responses when challenged with specific stimuli. 59 We were also able to detect the highly conserved binding sites of a TF called MEIS1, whose expression is not normally associated either with fear related behaviour or the amygdala. MEIS1 (myeloid ecotropic viral integration site 1) is a TF of the TALE class of homeodomain proteins that was first discovered as a result of its connection with myeloid leukaemia. 60 MEIS1 was subsequently found to be expressed in the fore brain and eyes of the developing embryo, where it is involved in supporting the proper embryonic development of these structures in addition to hematopoesis and development of the vasculature. 61 Remarkably, the human ECR1 enhancer contained no fewer than four different binding sites for MEIS1 (TGACAG 62 ), some of which had been conserved from a time prior to mammalianbird evolutionary divergence (310 million years). 40 Probability dictates that the six base pair consensus binding site of MEIS1 should only occur once in every 4 6 (16 384) base pairs within the human genome. Therefore, the extreme clustering and high degree of conservation of these binding sites within the 217 base pair human ECR1 enhancer, which we have shown is a tissue-specific enhancer, is highly significant (see Figure 1b) . Furthermore, many of these MEIS1 binding sites such as sites 1 and 2 have been highly conserved within mammals with site 1 being perfectly conserved for more that 310 million years between mammals and birds (see Figure 1b) . To determine the possibility of a functional relationship between MEIS1 and ECR1 in vivo, we carried out immunohistochemistry using anti-MEIS1 antibodies and were able to demonstrate in the current study that cells of the CeA, whose nuclei expressed the MEIS1 protein, also showed activity of the ECR1 enhancer. Together with the clustering and high conservation of its binding sites within ECR1, this exciting observation is entirely consistent with the hypothesis that the MEIS1 TF is involved in upregulating the activity of the ECR1 enhancer in the CeA in vivo. Furthermore, we present evidence that the MEIS1 protein can be found in either the cytoplasm or the nucleus, but is only associated with ECR1 activity when present in the nucleus (Figure 3 ). These data are entirely consistent with previous observations that describe the involvement of MEIS1 protein in the translocation of TFs such as PBX-1 and Drosophila Exd from the cytoplasm to the nucleus. 63, 64 These observations support the hypothesis that on receiving a specific cellular signal MEIS1 TF proteins, present in the cytoplasm, are translocated to the cell nucleus where they bind to ECR1 resulting in upregulation of PPTA expression.
We further propose that the involvement of the MEIS1 TF in maintaining the tissue specific activity of the ECR1 enhancer suggests a mechanism through which the ECR1 enhancer and, by extrapolation, the PPTA gene may be controlled in the amygdala. Several studies in the past have demonstrated a role of the cAMP/PKA signal transduction cascade within the amygdala in the generation of fear-related behaviour and memories. 65, 66 Although the cAMP/PKA signal transduction cascade has been shown to regulate the expression of PPTA in sensory neurones of the periphery, 67 the role of cAMP and PKA in regulating the expression of PPTA in the amygdala has been largely unexplored. The present study demonstrates that because the ECR1 enhancer is unable to support gene expression in sensory neurones, the mechanisms modulating ECR1 expression are different from those that control expression of PPTA in sensory neurones. Interestingly, it was recently demonstrated that MEIS1 is activated by phosphorylation by protein kinase A (PKA), a cAMP dependant kinase that is itself activated by adenylyle cyclases, 68 and binds a cAMP response element in the promotor of the bovine CYP17 gene. 69 Furthermore, the identification of several other highly clustered and remarkably conserved TF binding sites within ECR1 such as those of the ubiquitously expressed NF-Y protein 70 and C/EBP, 71 whose binding activity are both influenced by PKA activity 72 is further suggestive of a role for the cAMP/PKA signal transduction cascade in modulating the activity of ECR1 and the PPTA gene.
Many receptors expressed on the surface of central and medial amygdaloid neurones are known to mediate their cellular effects through the adenylyle cyclase/cAMP/PKA signal transduction pathway. Clues to the identity of the amygdala expressed receptors involved in modulating fear-related behaviour come from observations that following the application of a fearful stimulii serotonin and dopamine levels in the rodent amygdala were shown to be significantly elevated. 73 Therefore, candidates for the amygdaloid cell surface receptors that help modulate the activity of ECR1 through the cAMP/PKA signal transduction pathway include several members of the dopamine receptor family (D1 and D2) 74, 75 and the serotonin receptor family (2A, B2) . 76, 77 The serotonin and dopamine receptors are also known to be expressed in neurones of the CeA and MeA and have been shown to mediate their effects through a cAMP/ PKA signal transduction pathway. Modulation of ECR1 activity may also be subject to control via aminergic pathways such as glutamate that is known to influence mood through NMDA receptors that are expressed in the CeA (NR1 and NR2B) 78 and which are also known to influence fear related learning 79 via the cAMP/PKA signal transduction pathway. 80 In addition, the amygdala contains the receptors of various endocrine compounds such as glucocorticoids and epinephrine that are known to be elevated during the stress response and bind to members of the glucocorticoid receptor family and the adrenoceptors. 81 Using transgenic lines that express marker genes in the amygdala under the influence of ECR1, we are currently exploring the possible mechanisms linking the innervation of the CeA and MeA by monoaminergic, aminergic and neuropeptidinergic neural pathways, as well as endocrine sources known to modulate SP expression in the amygdala, using a variety of different ligand/receptor and signal transduction pathway agonists and antagonist. Deducing the components of these regulatory systems will provide an opportunity to discover how deficiencies within these systems may contribute to disease susceptibility. For example, the discovery of ECR1 will allow for a much more focused and mechanistic approach to identifying functional polymorphisms that may potentiate susceptibility to depressive and anxiety related disorders.
We have also recognised the potential therapeutic value of the ECR1 enhancer sequence. The vast majority of current therapies against depressive disorders entail the systemic application of compounds targeted against specific receptors and this approach is being explored with the development and testing of a variety of antagonists against the NK1 and NK2 receptors. However, efforts to develop such therapies against tachykinin receptors such as NK1, 2 and 3 may be frustrated by the broad distribution and wide variety of functions known to be modulated by the tachykinin receptors. For example, tachykinin receptors are distributed widely throughout the body 82 and regulate a wide range of physiological processes including blood pressure, 83, 84 emesis, 85 inflammation, 86 the immune response. 87 An alternative and promising approach to systemic drug therapy being currently explored involves the use of gene therapy. Again, however, a major obstacle preventing the development of cell and tissue-specific gene therapies against depressive diseases has been the unavailability of the required cell and tissue-specific enhancers that can direct the expression of therapeutic proteins into specific cell types. 88 We believe that the discovery of tissue specific enhancers that are capable of driving the expression of foreign proteins/ peptides into specific SP expressing cells in the amygdala is one that has tremendous potential for accelerating the development of tissue specific gene therapies. The development of these therapies will promise to treat, and possibly alleviate, depressive disorders while significantly reducing the occurrence of unacceptable side effects.
Conclusions
The identification and tissue specific characterisation of ECR1 represents an important step towards understanding the regulatory systems that control expression of the PPTA gene within the amygdala, where the products of PPTA play a role in the modulation of fear and anxiety. [89] [90] [91] The current study also showcases the power of applying comparative genomics, using the genomes of species as highly diverged as humans and birds, to gain insights into the regulatory mechanisms supporting the expression of genes relevant to mental health. This approach will greatly accelerate our identification and characterisation of the regulatory systems and networks required to drive the proper expression of neuronally expressed genes critical to human psychiatric health and will allow an understanding of how deficiencies within these systems might promote the initiation and progression of psychiatric disease.
